Department of Defense Awards $150,000 Grant to Founder of NeuroGenomeX, Inc. to Study Traumatic Brain Injury
March 2009, Madison, WI -- Dr. Thomas Sutula, chairman of the Department of Neurology at the University of Wisconsin-Madison and CSO of NeuroGenomeX, Inc. was awarded a $150,000 grant today from the Department of Defense (DoD) to study the neuroprotective efforts of the drug 2-deoxy-D-glucose (2DG) given after acute Traumatic Brain Injury (TBI). Post traumatic epilepsy is a common and unfortunate consequence of TBI. Dr. Sutula’s studies aim to determine whether 2DG can prevent or mitigate the structural brain damage and long-term post-traumatic epilepsy that result from TBI.
This work extends Dr. Sutula’s prior studies with 2DG as an anti-epileptic agent for patients with intractable epilepsy that has been demonstrated to be an effective inhibitor of epilepsy by a completely different mechanism of action compared to existing anti-epilepsy drugs.